 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || 9MW0813 (aflibercept biosimilar) / Mabwell (Shanghai) Biosci, Eylea (aflibercept intravitreal) / Bayer, Regeneron
New P1 trial: Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema (clinicaltrials.gov) - Apr 11, 2022
P1, N=24, Completed, Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- |||||||||| 9MW0813 (aflibercept biosimilar) / Mabwell (Shanghai) Biosci, Eylea (aflibercept intravitreal) / Bayer, Regeneron
New P3 trial: Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema (clinicaltrials.gov) - Apr 11, 2022
P3, N=346, Recruiting, Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.